Macular Edema

Rezolute Inc (NASDAQ: RZLT) has announced positive topline results from Phase 1a clinical study evaluating RZ402 to treat diabetic macular edema (DME). Single-dose oral administration of RZ402 resulted in plasma concentrations that substantially exceeded target...

Shares of Clearside Biomedical Inc (NASDAQ: CLSD) has 91 percent upside, according to a note from Stifel, which initiated coverage of the stock with a Buy rating and $13 price target. "Clearside has developed a novel ocular injection platform to deliver drug[s] optimally throughout the eye by way...

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were trading at new all-time high levels on Wednesday afternoon on concerns that rival Allergan (NYSE: AGN) may have problems moving its unnamed vision-loss drug into late-stage trials. The speculation is that Allergan believes it may have...